Coya Therapeutics Inc (COYA) FinancialsCOYACoya Therapeutics Inc

Evaluating the bottom line, Coya Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2890.45%, while the net margin is -2723.44%. These profitability ratios, combined with a Return on Equity (ROE) of -60.54%, provide a clear picture of how effectively COYA converts its operational activities into shareholder value.

In the context of the broader market, COYA competes directly with industry leaders such as ONCY and SEER. With a market capitalization of $112.36M, it holds a leading position in the sector. When comparing efficiency, COYA's gross margin of 100.00% stands against ONCY's N/A and SEER's 98.71%. Such benchmarking helps identify whether Coya Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Coya Therapeutics has shown substantial revenue growth, with Q1 2026 revenue at $251.1 million, although it continues to report net losses, such as $7.2 million in Q1 2026.